Drugs / AMTX-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04313400 | Mar 2020 → Dec 2023 | atopic eczema | Amytrx Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMTX-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04313400 ↗ |
| Modality | Peptide | “a 28-amino acid synthetic polypeptide (AMTX-100) as the active pharmaceutical ingredient (API)” NCT04313400 ↗ |
| Route | Topical | “topically applied twice a day” NCT04313400 ↗ |